medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2001, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2001; 48 (2)

Acute myocardial infarction, incidence and mortality at 30 days after thrombolysis with streptokinase

Vallejo-Uribe GO, Ledesma-Feret JA, Arriaga-Nava R

Language: Spanish
References: 40
Page: 78-82
PDF size: 37.01 Kb.


ABSTRACT

One of the illnesses more frequently observed in the Emergency Services it is the Acute Myocardial Infarction, however, from the beginning of the thrombolytic therapy it has diminished the mortality joined to the conventional treatment. Objective: Establish the incidence of the Acute Myocardial Infarction in the population above 18 years, time of thrombolytic therapy with SK after beginning of symptoms, as well as the mortality at 30 days. Design of the study: Prospective, observational, descriptive and longitudinal. Location: Emergency Services of the Hospital General de Zona 1 A; June 01 at December 31, 1999. Material and methods: patients of any gender, above 18 years with Acute Myocardial Infarction and Thrombolytic Therapy in Hospital GZ 1 A; clinic course, survival rates (Kaplan-Meier analysis). Results: Whit incidence of Acute Myocardial Infarction was 51 patients among 2 724 consultation granted in the service, thrombolysis therapy was employed in 14 cases (10 were males and 4 females); the average from the beginning of the symptoms the thrombolytic therapy was 3 hours. Mortality was 14.3% at 30 days. Discussion: The Acute Myocardial Infarction incidence was low, however, the number of cases is not big and we will be expect the analysis in a huge number of patients. The survival to 30 days observed in our study was of 85.7%.


REFERENCES

  1. Braunwald E. Infarto Agudo del Miocardio. Tratado de Cardiología. 4ª Ed. Madrid (España); Interamericana 1993.

  2. Lacy-Niebla MC. Cardiopatía isquémica en la mujer. Temas de Medicina Interna 1996; 4(3): 497-505.

  3. Peña-Luque MA. Infarto Agudo del Miocardio. Temas de Medicina Interna 1996; 4(3): 545-562.

  4. Cavazos-RJ. Epidemiología del Infarto del Miocardio en México. Tesis recepcional 1965.

  5. Ramos-Corrales MA. Nueva oportunidad para el paciente con infarto. Nueva Cardiología 1992; 2(7): 2-24.

  6. Rich-Edwards JW, Manson JE, Hennekens Ch, Buring JE. The primary prevention of coronary heart disease in woman. New Engl J Med 1995; 332(26): 1758-1766.

  7. Quevedo-RC, Hernández-FE. Trombólisis en IAM en HGZ 1 A “Los Venados”. Tesis recepcional 1995.

  8. González C, Stern MP, Mitchel B, Arredondo B, Martínez S, Seoane M. Myocardial Infarction in a low income area in Mexico city. Prevalence and clinical characteristics. Arch Med res 1995; 26: 233-238.

  9. Tlatempa-Martínez RE. Epidemiología del IAM en el Hospital de Cardiología del Centro Médico Nacional Siglo XXI. Tesis recepcional 1999.

  10. Badui E, Rangel A. Infarto agudo del miocardio en adultos jóvenes. Presentación de 142 casos. Arch Inst Cardiol Mex 1993; 63: 529-537.

  11. Camacho-Hernández R, Corona-Muñiz I, Vázquez-Martínez JL, Martínez-Rodríguez F, Escobedo-de la Peña F. Factores de riesgo para cardiopatía isquémica en México: un estudio de casos clínicos y testigos. Arch Inst Cardiol Mex 1995; 65: 315-322.

  12. Rubín SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and excess risk for coronary heart disease. Ann Med Int 1990; 113(2): 916-919.

  13. Peña Ruiz-Bravo GA, Otero-Cogide F, Lerdo de Tejada A, Espinoza-Legorreta M. Factores de riesgo coronario en una población de trabajadores del Instituto Mexicano del Seguro Social. Rev Mex Cardiol 1993; 4(1): 19-26.

  14. Luque-Coqui A. La hipótesis de arteria abierta: ¿un mito? Rev Mex Card 1994; 5(3): 69-71.

  15. Schand RC, O´Rourke RA, Callen D, Kennedy JW, Kuschnir E, Meyer J et al. Reperfusión en el IAM. Arch Inst Cardiol Mex 1994; 64: 373-387.

  16. Hussain KMA, Gould L, Soler B, Bharathan T, Reddy CV. Clinical science review: Current aspects of thrombolytic therapy in woman with acute myocardial infarction. Angiology 1996; 7(1): 23-33.

  17. Martínez-SC, Aguirre-S JS. Trombólisis coronaria. Rev Iberolat C Int 1996; 5(2): 76-85.

  18. Committee on Management of Myocardial Infarction for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart association Task Force on Practice Guidelines. J Am Coll Cardiol 1996; 28: 1328-1428.

  19. ACC/AHA Grupo de trabajo. Directrices de la ACC/AHA para el tratamiento de los pacientes con IAM. JACC (Ed. Mex.) 1997; 6(2): 29-53.

  20. Informe de la sección de cardiopatía isquémica de la Sociedad Española de Cardiología. Trombólisis y angioplastía coronaria en el IAM. Rev Esp Cardiol 1990; 43(8): 519-526.

  21. Sanz-Romero G, Cavadés-O´Callaghan A, Fernández-Palomeque C, López-Bescás L, Martín-Huerta E, Pajarón-López A et al. Informe sobre el tratamiento trombolítico en cardiología. Rec Esp Cardiol 1993; 46(11): 26-38.

  22. Boersma E, Simoons ML. Reperfusion strategies in acude myocardial infarction. European Heart J 1997; 18: 1703-1711.

  23. Pérez-Villa F, García-Dorado D. Detección de reperfusión en pacientes con IAM. Rev Esp Cardiol 1992; 45(Suppl 2): 72-83.

  24. Collen D. Is the an optimal thrombolytic regiment? Coronary Artery Disease 1994; 5: 287-291.

  25. Gruppo Italiano per lo studio della streptochinasi nell´infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in AMI. Lancet 1986; 1: 397-402.

  26. The ISAM Study Group: A prospective trial of intravenous streptokinase in AMI (ISAM). New Engl J Med 1986; 314(23): 1465-1471.

  27. Fibrinolytic Therapy Trialists´(FTT) Colaborative Group. Indications for fibrinolytic therapy in suspectell acute myocardial infarction: Collaborative overview of early mortality and mayor morbilidity results from al randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322.

  28. GISSI Gruppo: Long-term effects of intravenous thrombolytic in AMI: final report of the GISSI Study. Lancet 1987: 871-874.

  29. ISSIS-2 (Second international study of infarct survival) collaborative group: Randomized trial of intravenous streptokinase, oral aspirine both or neither among AMI: ISIS-2. Lancet 1988: 349-360.

  30. Third International study of Infarct survival, Collaborative group. ISIS-3 a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and aspirine plus heparin alone among 41,299 cases of suspected AMI. Lancet 1992; 339(8796): 753-781.

  31. The GUSTO investigators. An International randomized trial comparing four thrombolytic strategies for AMI. New Engl J Med 1993; 329(10): 673-682.

  32. GUSTO II b, Angioplasty substudy investigators: A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for AMI. New Engl J Med 1997; 336(23): 1621-1628.

  33. Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur (EMERAS) Collaborative group: Rabndomised trial of late thrombolytic in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-772.

  34. National Heart Attack Program Coordinating Committee, 60 minutes to treatment Working Group. Emergency department: rapid identification and treatment of patients with AMI. Ann Emerg Med 1994; 23: 311-329.

  35. Lefkovits J, Topol EJ. Future directions in thrombolisis for AMI: what are the unanswered question? Coronary Artery Disease 1994; 5: 306-316.

  36. LATE Study group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours onset of AMI. Lancet 1993; 342: 759-766.

  37. García-Mollinedo ML, Jerjes-Sánchez C, Ruiz de Chávez-Cervantes A. Revalidando los criterios de reperfusión no invasivos en pacientes con IAM sometidos a trombólisis farmacológica (Parte I): Arch Inst Cardiol Méx 1993; 63: 463-468.

  38. De la Peña-Almaguer E, Márquez MF, Eid-Lidt G, Férez-Santander SM. Daño miocárdico por reperfusión: su impacto en la clínica. Parte II. Arch Inst Cardiol Méx 1998; 68: 526-538.

  39. ACC/AHA Practice Guidlines for the management of patients with AMI. JACC 1999; 34(3): 890-911.

  40. Golbert R.J, Gore JM, Alpert JS, Osganian V, De Groot J, Bade J et al. Cardiogenic shock after acute myocardial infarction. Incidence and Mortality from a Community-wide Perspective, 1975-1988. New Engl J Med 1991; 325(16): 1117-1121.




2020     |     www.medigraphic.com